Lymphoma is cancer of the lymphatic system, divided into Hodgkin and non-Hodgkin types with dozens of subtypes. Many lymphomas are now highly treatable or curable with chemotherapy, immunotherapy, or targeted drugs, though aggressive forms and relapsed disease remain challenging.
What's actually going on in research
Trials are testing CAR T-cell therapy for earlier lines of treatment, bispecific antibodies that redirect immune cells to cancer, next-generation BTK inhibitors for B-cell lymphomas, and antibody-drug conjugates that deliver chemotherapy directly to tumor cells. Researchers are also studying ways to avoid or reduce chemotherapy in people whose lymphomas respond well to newer agents.
CAR T-cell therapy expansion
CAR T-cell therapy, where a person's immune cells are engineered to attack lymphoma, was approved for relapsed disease and is now being tested as earlier treatment. Trials are comparing it to standard chemotherapy combinations to see if it can replace harsher regimens.
Bispecific antibodies
These drugs attach to both a cancer cell and an immune cell, forcing them together so the immune system destroys the tumor. Several bispecifics are FDA-approved for relapsed lymphoma, and trials are testing them in newly diagnosed disease.
Chemotherapy-free regimens
Some lymphomas respond so well to targeted drugs or immunotherapy that trials are testing whether chemotherapy can be skipped entirely. Early results in certain subtypes show similar outcomes with fewer side effects.
What to know before you search
Eligibility typically depends on lymphoma subtype, stage, number of prior treatments, organ function, and sometimes specific genetic markers in the tumor.
What types of trials are currently open
- CAR T-cell trials — Testing engineered immune cells as earlier treatment, in combination with other drugs, or using next-generation CAR T designs with fewer side effects.
- Bispecific antibody trials — Testing drugs that link cancer cells to immune cells, often given as infusions or injections, to see if they work in earlier disease or with fewer treatments.
- Targeted therapy trials — Testing BTK inhibitors, PI3K inhibitors, and other drugs that block specific pathways lymphoma cells need to survive.
- Antibody-drug conjugate trials — Testing antibodies attached to chemotherapy that deliver the drug directly to lymphoma cells, sparing healthy tissue.
- Combination trials — Testing new drugs added to standard chemotherapy, or testing whether chemotherapy can be reduced or eliminated when combined with newer agents.
Recently added Lymphoma trials
Receive proton therapy for chest lymphoma
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
Share your medical records to help us understand a rare childhood leukemia
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
Find Lymphoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.